Hydrogen: the Swiss-army knife element

Few companies in the world can say they’ve been working with hydrogen for as long as Nel.

That’s why Bjorn Simonsen, who, until recently, was Nel’s Vice President for Investor Relations and Corporate Communication, said the company’s history aligns with and has driven how humans work with hydrogen.

“Nel has been involved in the entire development, from the early beginnings until today. Nel has consistently been a pioneer in the field with many firsts, both with regards to the industry with the 700 megawatts of electrolyser capacity installed in Norway for fertilizer production to the world’s first publicly available hydrogen fueling station, which opened in Reykjavik in 2003.”

Simonsen also recalled that the next year Nel powered the world’s first power-to-power project, providing 10 households on the island of Utsira power from stored hydrogen produced by excess wind power – something that made those homes the envy of the island when the rest of the grid went down during an important televised soccer match.

Nel has continued to innovate, becoming listed on the Oslo Stock Exchange and constructing the world’s largest manufacturing plant for hydrogen fueling stations as demand continues to increase for hydrogen solutions.

While some are skeptical hydrogen’s current uptick is another climb preceding a fall in a cycle of peaks and valleys, Simonsen has no doubt hydrogen is here to stay, since it solves so many of the issues our world is facing today.

“It’s super abundant. You can produce hydrogen anywhere in the world and can do that with zero emissions from production to use. And its nature’s own Swiss-army knife element, being both an ingredient and being an energy carrier,” he said.

That’s why, even after leaving Nel to become CEO of Saga Pure, he’ll still be cheering the growth of the hydrogen industry in his new role.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More